Neurocrine Biosciences Inc (NBIX) Investor Brief
A transitional profile paired with a halal-compliant screen and the main return and risk takeaways.
Neurocrine Biosciences Inc's growth score of 3.1 out of 4 and maturity score of 2.6 out of 4 still describe a transitional profile rather than a settled one. Product concentration and regulatory exposure leave the case more dependent on execution.
Move through the brief chapter by chapter, from Halal screening and business direction to return interpretation and the final takeaway.
Neurocrine Biosciences Inc (NBIX) does not need an institutional-style memo to be useful. A clearer read starts with Halal standing, business quality, and the shape of recent returns. Neurocrine Biosciences Inc is currently assessed as halal compliant, and the business profile presently reads as transitional when the growth and maturity signals are considered together.
How to think about stocks
Get occasional insight on how to evaluate stocks, not just what stock to look at next. We write when there is something genuinely useful to add.
By subscribing, you agree to receive this optional email and can withdraw consent later. Read the privacy policy.
At a Glance
Neurocrine Biosciences Inc is currently being reviewed as a healthcare company. Its market capitalization sits around 15.8B USD. The latest EBIT margin is about 22.3%.
The score mix looks transitional rather than settled, with growth score at about 3.1 out of 4 and maturity score around 2.6 out of 4, which often means the business is still proving what kind of long-term profile it wants to become. The resilience signal is mixed, suggesting the business profile has support, but not a particularly deep cushion. The cleaner support currently comes from Cash Cycle Strength and Cashflow Strength, and the resilience score itself sits around 3.0 out of 5.
Is NBIX Stock Halal?
Neurocrine Biosciences Inc is currently assessed as halal compliant. It operates in a Halal-compliant industry. The one-year forward screen currently leans toward Neurocrine Biosciences Inc being expected to remain compliant within the coming year.
On the financial screen, interest income is around 3.16% versus the AAOIFI threshold of 5.00%, debt is around 2.86% versus the AAOIFI threshold of 30.00%, securities is around 9.63% versus the AAOIFI threshold of 30.00%. These thresholds follow AAOIFI-based screening standards used in purepofo’s methodology. For a non-specialist investor, the key takeaway is that the financial side of the Halal screen does not currently look under obvious pressure.
| Financial ratio | Current level | Threshold |
|---|---|---|
| Interest Income | 3.16% | 5.00% |
| Debt | 2.86% | 30.00% |
| Securities | 9.63% | 30.00% |
What Does Neurocrine Biosciences Inc Do?
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States.
The score mix looks transitional rather than settled, with growth score at about 3.1 out of 4 and maturity score around 2.6 out of 4, which often means the business is still proving what kind of long-term profile it wants to become.
Investors can see the support most clearly in Market Expansion, Income Growth, Profit Stability and Cashflow Stability, but they should not ignore Valuation Momentum and Risk-Adjusted Returns as remaining constraints.
Return Snapshot: NBIX 1-Year, 3-Year, and 5-Year ROI
Return history is more helpful when it is framed as a pattern rather than as three disconnected statistics. The latest 1-year ROI is +7.9%. The trailing 3-year compounded ROI is +42.0%. The longer 5-year compounded ROI is +63.7%.
Returns look strongest over the longer period, suggesting the stock has rewarded patience even if the latest stretch is less spectacular. The Sharpe profile asks for more caution because the return path has not been especially clean.
Analyst targets place the stock around 211.72 USD versus a current level near 155.13 USD, implying roughly +36% across 16 analyst estimates. That is a market expectation, not an investment guarantee.
What Looks Good and Which NBIX Risks to Watch
The clearest positives are a rewarding longer-term return record, market expansion and income growth.
The risk picture is centered most clearly on product concentration and regulatory exposure.
Bottom Line: Is NBIX a Good Stock to Buy?
From an accessibility-first investor lens, Neurocrine Biosciences Inc is an execution-led candidate: growth at 3.1 out of 4 and maturity at 2.6 out of 4, which still describes a transitional business profile, so a stronger operating record would make the case easier to underwrite.
Use the investor brief as a starting point, then continue into the broader purepofo research workflow when you want deeper methodology, screening, or comparative context.
This article is provided for informational and educational purposes only. It does not constitute investment, legal, tax, Shariah, or other professional advice, and it is not a recommendation or solicitation to buy, sell, or hold any security. The content is general in nature, is not tailored to your personal circumstances or objectives, and should not be relied on as the sole basis for any investment decision.
Halal assessments, ratings, forecasts, and classifications reflect purepofo's methodology at the time of publication. They may change as company fundamentals, market data, methodology inputs, AAOIFI-based screening interpretations, or other information change. Proprietary scores and forward-looking assessments are inherently uncertain and are not guaranteed to be accurate, complete, or timely.
Third-party data may be used. purepofo does not guarantee the accuracy, completeness, or timeliness of third-party information and is not responsible for errors, omissions, or content provided by others. Logos and trademarks remain the property of their respective owners and are used for identification only.
You should carry out your own research and, where appropriate, consult qualified financial, legal, tax, and Shariah advisers before making any decision. Please also review our Terms and Conditions.
powered by innovation.
© 2026 purepofo.
All rights reserved.
Follow us on
